SITC Resource Library

Presentation slides and video from the 2024 Advances in Cancer Immunotherapy^™ (ACI) Series: A Focus on Pathology were presented virtually on December 10, 2024.

Program Organizers

• Janis M. Taube, MD, MSc - Johns Hopkins University School of Medicine
• Julie Stein Deutsch, MD - Johns Hopkins University School of Medicine

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Program Learning Objectives

• Discuss predictive markers in clinical use with cancer immunotherapies and their relevance to cancer immunotherapy approaches.
• Summarize recent updates in newly approved FDA immunotherapies and their impact on diagnostics.
• Describe the importance of pathological response evaluation and its correlation with outcomes, specifically in the neoadjuvant setting.
• Implement spatial biology-based approaches, such as multiplex fluorescence to assess immuno-oncological markers and patient response.
  

You can view the program agenda here.

Please note on-demand recordings are not available for continuing education credits.